Gengwei Huo, Gengwei Huo, Gengwei Huo, Gengwei Huo, Ying Song, Wei Liu, . . . Peng Chen. (2024). Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer. Frontiers Media S.A..
Chicago Style (17th ed.) CitationGengwei Huo, et al. Cost-effectiveness of Dostarlimab Plus Chemotherapy for Primary Advanced or Recurrent Endometrial Cancer. Frontiers Media S.A., 2024.
MLA (9th ed.) CitationGengwei Huo, et al. Cost-effectiveness of Dostarlimab Plus Chemotherapy for Primary Advanced or Recurrent Endometrial Cancer. Frontiers Media S.A., 2024.
Warning: These citations may not always be 100% accurate.